DexCom, Inc. (NASDAQ:DXCM) Shares Bought by APG Asset Management US Inc.

APG Asset Management US Inc. grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 14.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 209,914 shares of the medical device company’s stock after buying an additional 25,951 shares during the period. APG Asset Management US Inc. owned 0.05% of DexCom worth $23,546,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Capital World Investors boosted its holdings in shares of DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Capital Research Global Investors boosted its stake in DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after buying an additional 2,695,296 shares during the last quarter. Sands Capital Management LLC boosted its stake in DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after buying an additional 1,398,136 shares during the last quarter. Congress Asset Management Co. MA increased its stake in shares of DexCom by 2,076.3% in the 4th quarter. Congress Asset Management Co. MA now owns 1,126,382 shares of the medical device company’s stock worth $139,773,000 after acquiring an additional 1,074,626 shares during the last quarter. Finally, Winslow Capital Management LLC increased its stake in shares of DexCom by 26.5% in the 4th quarter. Winslow Capital Management LLC now owns 2,347,459 shares of the medical device company’s stock worth $291,296,000 after acquiring an additional 491,942 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The disclosure for this sale can be found here. Insiders sold 2,483 shares of company stock worth $201,708 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of several analyst reports. Redburn Atlantic assumed coverage on shares of DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. Royal Bank of Canada reduced their price objective on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Wells Fargo & Company lowered their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. BTIG Research dropped their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Morgan Stanley decreased their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Six equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Stock Down 2.8 %

DexCom stock opened at $66.73 on Thursday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $26.54 billion, a P/E ratio of 43.05, a P/E/G ratio of 2.16 and a beta of 1.18. The stock’s fifty day simple moving average is $75.42 and its 200-day simple moving average is $108.17. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue was up 15.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.34 earnings per share. As a group, equities analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.